122 related articles for article (PubMed ID: 7525515)
1. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma.
Avilés A; Delgado S; Nambo MJ; Alatriste S; Díaz-Maqueo JC
Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):799-803. PubMed ID: 7525515
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome.
Avilés A; Fernándezb R; Pérez F; Nambo MJ; Neri N; Talavera A; Castañeda C; González M; Cleto S
Leuk Lymphoma; 2004 Jul; 45(7):1385-9. PubMed ID: 15359637
[TBL] [Abstract][Full Text] [Related]
3. MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Bartlett NL; Kwak LW; Horning SJ
Cancer; 1993 Jun; 71(12):4034-42. PubMed ID: 7685238
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
[TBL] [Abstract][Full Text] [Related]
5. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy versus combined therapy in early stages with bulky disease aggressive malignant lymphoma.
Avilés A; Fernández R; Calva A; Neri N; Huerta-Guzmán J; Nambo MJ
Hematology; 2003 Feb; 8(1):7-10. PubMed ID: 12623421
[TBL] [Abstract][Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
9. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
Laver JH; Mahmoud H; Pick TE; Hutchison RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ
Leuk Lymphoma; 2002 Jan; 43(1):105-9. PubMed ID: 11908712
[TBL] [Abstract][Full Text] [Related]
10. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
[TBL] [Abstract][Full Text] [Related]
12. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
[TBL] [Abstract][Full Text] [Related]
13. Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
Ohnoshi T; Hayashi K; Ueno K; Tada A; Mizuta J; Tagawa S; Matsutomo S; Saito S; Kawashima K; Yoshino T
Int J Hematol; 1993 Aug; 58(1-2):93-8. PubMed ID: 7693030
[TBL] [Abstract][Full Text] [Related]
14. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
[TBL] [Abstract][Full Text] [Related]
15. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
16. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation.
Fuller LM; Krasin MJ; Velasquez WS; Allen PK; McLaughlin P; Rodriguez MA; Hagemeister FB; Swan F; Cabanillas F; Palmer JL
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):3-11. PubMed ID: 7527799
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
Avilés A; Calva A; Díaz-Maqueo JC; Talavera A; Huerta-Guzmán J; Vásquez E
Leuk Lymphoma; 1997 Apr; 25(3-4):319-25. PubMed ID: 9168442
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
19. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma.
Avilés A; Neri N; Huerta-Guzmán J; Pérez F; Sotelo L
Leuk Lymphoma; 2004 Nov; 45(11):2247-51. PubMed ID: 15512813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
